Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.

Authors: Maggini, V  Buda, G  Galimberti, S  Conidi, E  Giuliani, N  Morabito, F  Genestreti, G  Iacopino, P  Rizzoli, V  Barale, R  Petrini, M  Rossi, AM 
Citation: Maggini V, etal., Leuk Res. 2008 Jan;32(1):49-53. Epub 2007 May 23.
Pubmed: (View Article at PubMed) PMID:17512053
DOI: Full-text: DOI:10.1016/j.leukres.2007.03.029

This study examines the response to dexamethasone-doxorubicin-vincristine (DAV) therapy, followed by conditioning regimen and autologous stem cells transplantation (ASCT) in patients with multiple myeloma in relation with the presence of polymorphisms in genes involved in drug metabolism (GSTP1) and DNA synthesis (TYMS). GSTP1 G313G genotype (OR=5.49; 95% CI, 1.3-22.5, p=0.02) and TYMS A227A genotype (OR=3.41; 95% CI, 1.3-8.9, p=0.01) resulted significantly associated with a poor response following chemotherapy and the risk increased for the combined genotype (OR=13.54; 95% CI, 2.0-91.3, p=0.01). TYMS T157T genotype was significantly associated with a poor response after ASCT (OR=4.60; 95% CI, 1.2-16.9, p=0.02). Pre-therapeutic individual determination of the GSTP1 and TYMS polymorphisms could help in choosing the most appropriate protocol.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11075094
Created: 2016-05-06
Species: All species
Last Modified: 2016-05-06
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.